Brief: Vir Biotechnology Says Tobevibart Monotherapy, Combination Therapy With Elebsiran Achieved High Virologic Response
05/06/2024 12:45
June 5 (Reuters) - Vir Biotechnology Inc VIR.O :
* VIR BIOTECHNOLOGY INC: TOBEVIBART MONOTHERAPY AND
COMBINATION
THERAPY WITH ELEBSIRAN ACHIEVED HIGH VIROLOGIC RESPONSE
Source text for Eikon: ID:nBw6ygQKba
Further company coverage: VIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO